ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial.
Journal of Clinical Oncology
◽
10.1200/jco.2016.34.15_suppl.4565
◽
2016
◽
Vol 34
(15_suppl)
◽
pp. 4565-4565
◽
Cited By ~ 5
Author(s):
Ai-Ping Zhou
◽
Jianhui Ma
◽
Yuxian Bai
◽
Yan Song
◽
Hangzhong Li
◽
...
Keyword(s):
Clinical Trial
◽
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Phase Ii
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Line Treatment
◽
First Line
◽
Randomized Phase Ii
◽
First Line Treatment
Download Full-text
Related Documents
Cited By
References
Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
The Oncologist
◽
10.1634/theoncologist.2018-0839
◽
2019
◽
Vol 24
(8)
◽
Cited By ~ 9
Author(s):
Ai‐Ping Zhou
◽
Yuxian Bai
◽
Yan Song
◽
Hong Luo
◽
Xiu‐Bao Ren
◽
...
Keyword(s):
Clinical Trial
◽
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Phase Ii
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Line Treatment
◽
First Line
◽
Randomized Phase Ii
◽
First Line Treatment
Download Full-text
Commentary on Randomized phase II trial of first-line treatment with sorafenib vs. interferonα-2a in patients with metastatic renal cell carcinoma
Urologic Oncology Seminars and Original Investigations
◽
10.1016/j.urolonc.2009.07.007
◽
2009
◽
Vol 27
(5)
◽
pp. 572
Author(s):
Donald L. Trump
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Phase Ii
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Phase Ii Trial
◽
Line Treatment
◽
First Line
◽
Randomized Phase Ii
◽
First Line Treatment
Download Full-text
Randomized phase II study of sunitinib + CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.
Journal of Clinical Oncology
◽
10.1200/jco.2015.33.15_suppl.4547
◽
2015
◽
Vol 33
(15_suppl)
◽
pp. 4547-4547
◽
Cited By ~ 1
Author(s):
John D. Hainsworth
◽
Joseph Ronald Mace
◽
James Andrew Reeves
◽
Edward J. Crane
◽
Oday Hamid
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Phase Ii
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Phase Ii Study
◽
Line Treatment
◽
First Line
◽
Randomized Phase Ii
◽
First Line Treatment
Download Full-text
LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)
Annals of Oncology
◽
10.1016/j.annonc.2021.08.2105
◽
2021
◽
Vol 32
◽
pp. S1304-S1305
Author(s):
N.S. Vasudev
◽
G. Ainsworth
◽
S. Brown
◽
L. Pickering
◽
T.S. Waddell
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Phase Ii
◽
Renal Cell
◽
Phase Ii Trial
◽
Advanced Renal Cell Carcinoma
◽
Line Treatment
◽
First Line
◽
Randomized Phase Ii
◽
First Line Treatment
Download Full-text
PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma
Annals of Oncology
◽
10.1093/annonc/mdy283.140
◽
2018
◽
Vol 29
◽
pp. viii331
Author(s):
F. Collinson
◽
S. Brown
◽
H. Buckley
◽
G. Ainsworth
◽
H. Howard
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Phase Ii
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Phase Ii Trial
◽
Line Treatment
◽
First Line
◽
First Line Treatment
Download Full-text
7122 Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma (mRCC): preliminary results
European Journal of Cancer Supplements
◽
10.1016/s1359-6349(09)71455-7
◽
2009
◽
Vol 7
(2)
◽
pp. 429-430
◽
Cited By ~ 4
Author(s):
C.H. Barrios
◽
D. Hernandez-Barajas
◽
M.P. Brown
◽
S.H. Lee
◽
L. Fein
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Phase Ii
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Phase Ii Trial
◽
Line Treatment
◽
First Line
◽
Once Daily
◽
First Line Treatment
Download Full-text
Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma
Cancer
◽
10.1002/cncr.26440
◽
2011
◽
Vol 118
(5)
◽
pp. 1252-1259
◽
Cited By ~ 67
Author(s):
Carlos H. Barrios
◽
David Hernandez-Barajas
◽
Michael P. Brown
◽
Se-Hoon Lee
◽
Luis Fein
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Phase Ii
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Phase Ii Trial
◽
Line Treatment
◽
First Line
◽
Once Daily
◽
First Line Treatment
Download Full-text
Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
Yearbook of Urology
◽
10.1016/s0084-4071(09)79341-8
◽
2009
◽
Vol 2009
◽
pp. 104-106
Author(s):
D.E. Coplen
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Phase Ii
◽
Renal Cell
◽
Phase Ii Trial
◽
Interferon Alfa
◽
Line Treatment
◽
First Line
◽
Randomized Phase Ii
◽
First Line Treatment
Download Full-text
Faculty Opinions recommendation of Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.1157292.617430
◽
2009
◽
Author(s):
David M Nanus
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Phase Ii
◽
Renal Cell
◽
Phase Ii Trial
◽
Interferon Alfa
◽
Line Treatment
◽
First Line
◽
Randomized Phase Ii
◽
First Line Treatment
Download Full-text
A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma
European Urology
◽
10.1016/j.eururo.2021.03.016
◽
2021
◽
Author(s):
Irbaz Bin Riaz
◽
Huan He
◽
Alexander J. Ryu
◽
Rabbia Siddiqi
◽
Syed Arsalan Ahmed Naqvi
◽
...
Keyword(s):
Systematic Review
◽
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Meta Analysis
◽
Line Treatment
◽
First Line
◽
First Line Treatment
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close